Reprogramming of non-genomic estrogen signaling by the stemness factor SOX2 enhances the tumor-initiating capacity of breast cancer cells
- PMID: 24107627
- PMCID: PMC3906332
- DOI: 10.4161/cc.26692
Reprogramming of non-genomic estrogen signaling by the stemness factor SOX2 enhances the tumor-initiating capacity of breast cancer cells
Abstract
The restoration of pluripotency circuits by the reactivation of endogenous stemness factors, such as SOX2, may provide a new paradigm in cancer development. The tumoral stem cell reprogramming hypothesis, i.e., the ability of stemness factors to redirect normal and differentiated tumor cells toward a less-differentiated and stem-like state, adds new layers of complexity to cancer biology, because the effects of such reprogramming may remain dormant until engaged later in response to (epi)genetic and/or (micro)environmental events. To test this hypothesis, we utilized an in vitro model of a SOX2-overexpressing cancer stem cell (CSC)-like cellular state that was recently developed in our laboratory by employing Yamanaka's nuclear reprogramming technology in the estrogen receptor α (ERα)-positive MCF-7 breast cancer cell line. Despite the acquisition of distinct molecular features that were compatible with a breast CSC-like cellular state, such as strong aldehyde dehydrogenase activity, as detected by ALDEFLUOR, and overexpression of the SSEA-4 and CD44 breast CSC markers, the tumor growth-initiating ability of SOX2-overexpressing CSC-like MCF-7 cells solely occurred in female nude mice supplemented with estradiol when compared with MCF-7 parental cells. Ser118 phosphorylation of estrogen receptor α (ERα), which is a pivotal integrator of the genomic and nongenomic E 2/ERα signaling pathways, drastically accumulated in nuclear speckles in the interphase nuclei of SOX2-driven CSC-like cell populations. Moreover, SOX2-positive CSC-like cells accumulated significantly higher numbers of actively dividing cells, and the highest levels of phospho-Ser118-ERα occurred when chromosomes lined up on a metaphase plate. The previously unrecognized link between E 2/ERα signaling and SOX2-driven stem cell circuitry may significantly impact our current understanding of breast cancer initiation and progression, i.e., SOX2 can promote non-genomic E 2 signaling that leads to nuclear phospho-Ser118-ERα, which ultimately exacerbates genomic ER signaling in response to E 2. Because E 2 stimulation has been recently shown to enhance breast tumor-initiating cell survival by downregulating miR-140, which targets SOX2, the establishment of a bidirectional cross-talk interaction between the stem cell self-renewal regulator, SOX2, and the local and systemic ability of E 2 to increase breast CSC activity may have profound implications for the development of new CSC-directed strategies for breast cancer prevention and therapy.
Keywords: SOX2; breast cancer; cancer stem cells; estradiol; estrogen receptor.
Figures
![None](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3906332/bin/cc-12-3471-g1.gif)
![None](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3906332/bin/cc-12-3471-g2.gif)
![None](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3906332/bin/cc-12-3471-g3.gif)
![None](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3906332/bin/cc-12-3471-g4.gif)
Similar articles
-
Understanding the function and regulation of Sox2 for its therapeutic potential in breast cancer.Biochim Biophys Acta Rev Cancer. 2022 Mar;1877(2):188692. doi: 10.1016/j.bbcan.2022.188692. Epub 2022 Feb 2. Biochim Biophys Acta Rev Cancer. 2022. PMID: 35122882 Review.
-
SOX2 and p53 Expression Control Converges in PI3K/AKT Signaling with Versatile Implications for Stemness and Cancer.Int J Mol Sci. 2020 Jul 11;21(14):4902. doi: 10.3390/ijms21144902. Int J Mol Sci. 2020. PMID: 32664542 Free PMC article. Review.
-
Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway.Cell Cycle. 2013 Sep 15;12(18):3109-24. doi: 10.4161/cc.26173. Epub 2013 Aug 21. Cell Cycle. 2013. PMID: 23974095 Free PMC article.
-
The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells.Oncogene. 2014 Jan 30;33(5):599-610. doi: 10.1038/onc.2012.628. Epub 2013 Jan 21. Oncogene. 2014. PMID: 23334326 Free PMC article.
-
Estrogen receptor α signaling regulates breast tumor-initiating cells by down-regulating miR-140 which targets the transcription factor SOX2.J Biol Chem. 2012 Nov 30;287(49):41514-22. doi: 10.1074/jbc.M112.404871. Epub 2012 Oct 11. J Biol Chem. 2012. PMID: 23060440 Free PMC article.
Cited by
-
Role of hydroxymethylglutharyl-coenzyme A reductase in the induction of stem-like states in breast cancer.J Cancer Res Clin Oncol. 2024 Feb 28;150(2):106. doi: 10.1007/s00432-024-05607-7. J Cancer Res Clin Oncol. 2024. PMID: 38418798 Free PMC article.
-
Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance.Front Oncol. 2022 Mar 21;12:856974. doi: 10.3389/fonc.2022.856974. eCollection 2022. Front Oncol. 2022. PMID: 35392236 Free PMC article. Review.
-
SOX2 mediates metabolic reprogramming of prostate cancer cells.Oncogene. 2022 Feb;41(8):1190-1202. doi: 10.1038/s41388-021-02157-x. Epub 2022 Jan 24. Oncogene. 2022. PMID: 35067686 Free PMC article.
-
Unexplored Functions of Sex Hormones in Glioblastoma Cancer Stem Cells.Endocrinology. 2022 Mar 1;163(3):bqac002. doi: 10.1210/endocr/bqac002. Endocrinology. 2022. PMID: 35023543 Free PMC article. Review.
-
Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer.Pharmacol Rep. 2022 Apr;74(2):366-378. doi: 10.1007/s43440-021-00346-9. Epub 2022 Jan 9. Pharmacol Rep. 2022. PMID: 35000145
References
-
- Menendez JA, Vellon L, Oliveras-Ferraros C, Cufí S, Vazquez-Martin A. mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging. Cell Cycle. 2011;10:3658–77. doi: 10.4161/cc.10.21.18128. - DOI - PubMed
-
- Vazquez-Martin A, Vellon L, Quirós PM, Cufí S, Ruiz de Galarreta E, Oliveras-Ferraros C, Martin AG, Martin-Castillo B, López-Otín C, Menendez JA. Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells. Cell Cycle. 2012;11:974–89. doi: 10.4161/cc.11.5.19450. - DOI - PubMed
-
- Corominas-Faja B, Cufí S, Oliveras-Ferraros C, Cuyàs E, López-Bonet E, Lupu R, Alarcón T, Vellon L, Iglesias JM, Leis O, et al. Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway. Cell Cycle. 2013;12:3109–24. doi: 10.4161/cc.26173. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous